Articles tagged with Severe Combined Immunodeficiency
Researchers have identified genetic changes that can leave children born with little to no immune defense against infection. The study links mutations in the NUDCD3 gene to Severe Combined Immunodeficiency and Omenn syndrome, rare and life-threatening immunodeficiency disorders.
A new study shows that newborn screening for severe combined immunodeficiency disease (SCID) has significantly increased the survival rate of children after bone marrow transplantation from 73% to 87%. Children diagnosed at birth have a 92.5% survival rate without infection, while those diagnosed later have lower rates.
Widespread newborn screening for severe combined immunodeficiency (SCID) has increased the five-year survival rate from 73% to 87%, with 92.5% of children surviving five years or more after treatment. The study, led by NIAID, demonstrates that early identification and prompt treatment have saved countless lives.
Researchers at UCLA successfully used base editing to correct a mutation causing rare immune deficiency CD3 delta SCID. The treatment corrected an average of 71% of patient stem cells and allowed them to produce fully functional T cells, suggesting long-term persistence of corrected blood stem cells.
Researchers at Institut Pasteur found that immunocompromised patients experience disrupted immune mechanisms, including reduced production of antibodies and increased pathogenic bacteria, after a bone marrow transplant. This discovery could lead to more effective treatment protocols for these patients.
Researchers developed a gene therapy that successfully treated 48 out of 50 children with ADA-SCID, a rare life-threatening disease. The treatment involves removing stem cells, delivering a new copy of the ADA gene, and returning the corrected cells to produce healthy immune cells.
A new test developed at CHU Sainte-Justine enables better management of patients with severe combined immunodeficiency (SCID) by analyzing a small volume of peripheral blood. The test uses a 3D culture system to mimic the function of a human thymus, allowing for a relatively quick response and improved treatment options.
Warren J. Leonard is recognized for pioneering work in X-linked severe combined immunodeficiency and cloning the IL-2 receptor alpha chain. His findings led to a deeper understanding of cytokine signaling and immune dysregulation.
An international study published in Blood highlights the urgent need for better treatment strategies for patients with severe combined immune deficiency (SCID). The study found that survival rates were higher after cell transplants from matched sibling donors and that young age and absence of active infection were key factors for impro...
The UKPID registry has provided valuable information on PID in the UK, especially regarding delays to diagnosis. The data show that longer diagnostic delays can lead to poorer long-term outcomes for patients.
Severe combined immunodeficiency disease (SCID) is a rare, deadly condition that can be cured with early diagnosis and treatment. A new review provides guidance for pediatricians and doctors on identifying and treating SCID, aiming to save lives and prevent suffering.
A new study aims to find the lowest dose of chemotherapy needed for babies with severe combined immunodeficiency (SCID) undergoing bone marrow transplant. The goal is to restore the immune system safely and effectively with less toxicity than current regimens.
Researchers have developed a new testing regime to diagnose severe combined immune deficiency (SCID) syndrome faster, enabling more infants to receive life-saving treatment within a critical timeframe. The regime uses a checklist of potential SCID markers, including family history, candidiasis, and low absolute lymphocyte counts.
The St. Jude gene therapy program will deliver gene therapy to patients with X-linked severe combined immunodeficiency disease (X-SCID), also known as 'bubble boy' disease, at the University of California, San Francisco. The new grant supports widening access to this life-saving treatment for rare but deadly immune disease.
Gene therapy has made significant progress in treating X-linked severe combined immunodeficiency (SCID-X1), with hematopoietic stem cells showing promise for a cure. However, ongoing challenges include improving safety and achieving long-term immune reconstitution, highlighting the need for continued research and development.
Researchers at Salk Institute have developed a new method to convert cells from x-linked SCID patients into stem cell-like state, fix the genetic mutation and prompt corrected cells to successfully generate NK cells in the laboratory. This technique could lead to a more effective and less invasive treatment for this devastating disease.
A new study supports the use of newborn screening tests for severe combined immunodeficiency (SCID), a life-threatening condition affecting approximately 1 in 58,000 infants. The test identified 52 cases of SCID, with all patients receiving lifesaving treatments and 92% surviving.
The study reveals a higher incidence of SCID in newborns, with survival rates significantly improved through early detection and treatment. The expansion of newborn screening programs has led to better outcomes for affected infants.
A study analyzing over 3 million infants screened for SCID found an incidence rate of 1 in 58,000 births. The survival rate for SCID-affected infants is high at 87%, with further improvements seen when transplantation, enzyme replacement, and gene therapy are used.
Severe combined immunodeficiency (SCID) affects 1 in 58,000 infants, but recent screenings have detected nearly double the previously estimated incidence. The study found that infant screening programs can detect SCID early, allowing for timely treatment and improved survival rates.
A review of over 240 patient cases found transplants to be highly effective in treating severe combined immunodeficiency (SCID) in young children. Early transplantation without infection results in exceptionally good outcomes, with overall five-year survival rates ranging from 77-93%.
A study analyzing 10 years of data on children with severe combined immune deficiency (SCID) found that early detection through newborn screening and transplantation significantly improves survival rates. Children transplanted before 3.5 months old had excellent survival, regardless of donor source or infection status.
Pediatricians Rebecca H. Buckley and Jennifer M. Puck received the March of Dimes Lifetime Achievement Award in Genetics for laying the groundwork for early detection of severe combined immunodeficiency disease (SCID). Their research led to the development of a newborn screening test, significantly improving long-term survival rates.
Researchers have successfully restored the immune systems of some children with SCID using a refined gene therapy approach, eliminating the need for life-long injections. The treatment involves inserting a healthy copy of the ADA gene into bone marrow stem cells, preventing immune-destroying toxicity.
Researchers develop refined gene therapy approach that safely restores the immune system of children with ADA-deficient SCID. Chemotherapy conditioning regimen prior to treatment significantly increases ADA enzyme levels and partial immune reconstitution in patients.
Researchers at UCLA have developed a gene therapy regimen that safely restores immune systems to children with ADA-deficient severe combined immunodeficiency (SCID), a devastating disease. The treatment showed promising results in restoring immune function to three out of six patients, offering new hope for these children.
A study published in Blood demonstrates that newborn screening and early diagnosis of Severe Combined Immunodeficiency (SCID) can improve survival rates. Babies diagnosed at birth and receiving a hematopoietic stem cell transplant have significantly reduced infections and improved survival outcomes.
A study from Rhode Island Hospital found that patients over-diagnosed with bipolar disorder were more likely to receive disability payments for a longer period. The researchers propose a link between the two, suggesting that clinicians may over-diagnose bipolar disorder in complex, chronically ill patients seeking secondary gain.
A Wisconsin statewide blood screening program successfully identified newborns with T-cell lymphopenia, a severe immune disorder. The test, which analyzes DNA from dried blood spots, detected the condition in eight infants and showed promise as a cost-effective method for early diagnosis.
Most SCID children treated with related donor bone marrow transplants can lead normal lives, says a new study. The research found that those who received transplants within the first 14 weeks of life were more likely to survive and have fewer problems over time.
Researchers at Erasmus Medical Center have identified a new genetic cause of Severe Combined Immunodeficiency (SCID), also known as 'Boy in the bubble syndrome'. A mutation in the DNA-PKcs gene is found to be responsible for the disease, leading to impaired T cell and B cell development.
Researchers found that newborn screening for SCID could be cost-effective due to the benefits of early diagnosis and the potential to save lives. A two-tiered strategy combining existing tests has been shown to improve accuracy without increasing costs, making it a promising approach for nationwide screening programs.
Researchers investigate Akt1's impact on cardiac function, finding it can enhance cardiac function after heart failure but also contribute to maladaptive effects. A new gene therapy approach successfully treats severe combined immunodeficiency (SCID) in mice, offering promising implications for its treatment.
Researchers at UT Southwestern Medical Center have developed a new gene therapy technique that uses homologous recombination to replace mutated genes in human immune cells, restoring both gene function and protein production. This approach has shown promising results in treating severe combined immunodeficiency disease (SCID) and may a...
Researchers found that TLR9-induced protection is mediated through type I IFN induction, which suppresses inflammation. Type I IFN has a protective role in colon injury and protects against colonic inflammation.
The new test can identify babies born with Severe Combined Immunodeficiency (SCID), a life-threatening illness, early on, allowing for effective treatment. The test uses dried blood samples from newborns, providing the first accurate and high-throughput screen for immune deficiencies.
A new gene therapy approach has successfully corrected immunodeficiencies in 17 of 18 patients with severe combined immunodeficiency disease. The treatment, which involves introducing a 'good' gene into stem cells, has shown clear and sustained clinical benefits.
Researchers discovered a complete deficiency in the CD3 epsilon chain of the T cell receptor causes SCID, leading to normal B cells but no T cells development. The absence of this chain blocks T cell development at a specific stage in the thymus.
Researchers identified a complete deficiency in the CD3 epsilon chain of the T cell receptor causing SCID, leading to normal B cells but no T cells. Early diagnosis via bone marrow stem cell transplantation can result in a survival rate as high as 97% for patients with this mutation.
A simple, inexpensive blood test performed at birth can screen for immune disorders like SCID and increase survival rates. The test, which costs $50, identifies infants with a profound deficiency of lymphocytes and has been shown to be effective in identifying children with other immune disorders.
Researchers have successfully used gene therapy to treat two young children with ADA-SCID, a rare form of SCID that requires regular injections of the bovine form of ADA enzyme. The new method involves removing bone marrow cells and engineering them to produce healthy immune cells, offering a potentially lower-risk alternative to bone ...
Researchers at Duke University Medical Center found that stem cell transplants performed within the first 28 days of life have a 95 percent success rate in treating newborn babies with severe combined immunodeficiency (SCID). The early transplants also stimulate a more robust and effective immune system, with reduced stresses on the th...
French researchers develop gene therapy to treat human severe combined immunodeficiency (SCID) X1, a life-threatening disease. Two infants experience 'striking' clinical improvements and return to normal immune system functioning without side effects.
Doctors at Duke University Medical Center have developed a treatment that can save most babies born with severe combined immune deficiency (SCID) by giving them a family member's bone marrow within the first 3.5 months of life. This approach has eradicated the need for toxic chemotherapy, sterile environments, and lengthy hospital stays.
A Duke University Medical Center study reveals that early marrow transplants can cure nearly all cases of severe combined immune deficiency (SCID), a previously fatal disorder. The research found that treating the disease within three months of birth and using 'half-matched' parental marrow can significantly improve survival rates.